STRATEGY STUDIO / NONPROFIT PEOPLE SEARCH

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC (EIN 91-2059167)
Tax period
2011-01-01 to 2011-12-31
Filed
2012-08-24
IRS object ID
201212379349300631
Schema version
2011v1.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Timestamp2012-08-24T13:34:57-04:00Timestamp
Tax Period End Date2011-12-31TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

FieldValueIRS element (for citing)
Business Name Line1ARGY WILTSE & ROBINSON PCBusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

FieldValueIRS element (for citing)
Address Line18405 GREENSBORO DRIVE 7TH FLOORAddressLine1
CityMCLEANCity
StateVAState
ZIP Code22102ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnType
Tax Period Begin Date2011-01-01TaxPeriodBeginDate

Filer Filer

FieldValueIRS element (for citing)
EIN912059167EIN

Name Name

FieldValueIRS element (for citing)
Business Name Line1CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCBusinessNameLine1
FieldValueIRS element (for citing)
In Care Of Name% ROBERT J BEALL PHDInCareOfName
Name ControlCYSTNameControl
Phone3019514422Phone

US Address USAddress

FieldValueIRS element (for citing)
Address Line16931 ARLINGTON ROADAddressLine1
CityBETHESDACity
StateMDState
ZIP Code20814ZIPCode

Officer Officer

FieldValueIRS element (for citing)
NameROBERT J BEALL PHDName
TitlePRESIDENT & CEOTitle
Date Signed2012-08-23DateSigned
Authorize Third PartytrueAuthorizeThirdParty

Preparer Preparer

FieldValueIRS element (for citing)
NameDAVID J TRIMNERName
Phone7038930600Phone
FieldValueIRS element (for citing)
Tax Year2011TaxYear
Build TS2016-02-24 21:20:13ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Name Of Principal Officer PersonROBERT J BEALL PHDNameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

FieldValueIRS element (for citing)
Address Line16931 ARLINGTON ROAD STE 200AddressLine1
CityBETHESDACity
StateMDState
ZIP Code20814ZIPCode
FieldValueIRS element (for citing)
Gross Receipts100420758GrossReceipts
Group Return For AffiliatesfalseGroupReturnForAffiliates
Organization501c3XOrganization501c3
Web Sitewww.CFF.ORG/RESEARCH/CFFT/WebSite
Type Of Organization CorporationXTypeOfOrganizationCorporation
Year Formation2000YearFormation
State Legal DomicileMDStateLegalDomicile
Activity Or Mission DescriptionThe mission is to assure the development of the means to cure and control cystic fibrosis (cf) and to improve the quality of life for those with the disease.ActivityOrMissionDescription
Nbr Voting Members Governing Body7NbrVotingMembersGoverningBody
Nbr Independent Voting Members6NbrIndependentVotingMembers
Total Nbr Employees12TotalNbrEmployees
Total Nbr Volunteers0TotalNbrVolunteers
Total Gross UBI0TotalGrossUBI
Net Unrelated Business Txbl Income0NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year0ContributionsGrantsPriorYear
Contributions Grants Current Year99865046ContributionsGrantsCurrentYear
Program Service Revenue Prior Year400446ProgramServiceRevenuePriorYear
Program Service Revenue CY551511ProgramServiceRevenueCY
Investment Income Prior Year369InvestmentIncomePriorYear
Investment Income Current Year188InvestmentIncomeCurrentYear
Other Revenue Prior Year53761115OtherRevenuePriorYear
Other Revenue Current Year4013OtherRevenueCurrentYear
Total Revenue Prior Year54161930TotalRevenuePriorYear
Total Revenue Current Year100420758TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year29412613GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY27991951GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year0BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY0BenefitsPaidToMembersCY
Salaries Etc Prior Year2842375SalariesEtcPriorYear
Salaries Etc Current Year3008405SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year0TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY0TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year0TotalFundrsngExpCurrentYear
Other Expense Prior Year21906942OtherExpensePriorYear
Other Expenses Current Year19487879OtherExpensesCurrentYear
Total Expenses Prior Year54161930TotalExpensesPriorYear
Total Expenses Current Year50488235TotalExpensesCurrentYear
Revenues Less Expenses CY49932523RevenuesLessExpensesCY
Total Assets BOY67639625TotalAssetsBOY
Total Assets EOY28133165TotalAssetsEOY
Total Liabilities BOY67639625TotalLiabilitiesBOY
Total Liabilities EOY28133165TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY0NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY0NetAssetsOrFundBalancesEOY
Mission DescriptionTHE MISSION IS TO ASSURE THE DEVELOPMENT OF THE MEANS TO CURE AND CONTROL CYSTIC FIBROSIS (CF) AND TO IMPROVE THE QUALITY OF LIFE FOR THOSE WITH THE DISEASE. A LIFE SHORTENING GENETIC DISEASE, CF AFFECTS THE LUNGS AND DIGESTIVE SYSTEMS OF NEARLY 30,000 CHILDREN AND YOUNG ADULTS IN THE U.S. CURRENTLY, THERE IS NO CURE.MissionDescription
Significant New Program ServicesfalseSignificantNewProgramServices
Significant ChangefalseSignificantChange
Expense20415616Expense
Grants0Grants
Revenue0Revenue
DescriptionINVESTMENTS BY CYSTIC FIBROSIS FOUNDATION THERAPEUTICS (CFFT) IN STATE-OF-THE-ART RESEARCH HAVE ACCELERATED PROGRESS TOWARD DEVELOPING NEW CF TREATMENTS AND FINDING A CURE FOR THE DISEASE. BY INVESTING IN CF DRUG DISCOVERY AND DEVELOPMENT RESEARCH CONDUCTED BY BIOTECHNOLOGY COMPANIES AND PROVIDING MATCHING AWARDS TO CF DRUG DEVELOPERS FOR CF RESEARCH, AND WITH A SPECIALIZED CF CLINICAL TRIALS NETWORK, CFFT HAS ATTRACTED SIGNIFICANT INDUSTRY INVOLVEMENT IN THE FIGHT AGAINST CF. IN 2011, PHASE 3 CLINICAL TRIALS OF VX-770 SHOWED PROFOUND RESULTS. THOSE RECEIVING THE DRUG DEMONSTRATED THE HIGHEST INCREASE ON A LUNG FUNCTION TEST SEEN IN ANY CLINICAL TRIAL OF A CF DRUG. A NEW DRUG APPLICATION TO THE FDA FOR VX-770 UNDER THE TRADE NAME KALYDECO WAS SUBMITTED BY VERTEX PHARMACEUTICALS. RESULTS FROM THE FIRST PART OF AN ONGOING PHASE 2 TRIAL TESTING KALYDECO IN COMBINATION WITH VX-809 SHOW PROMISING RESULTS IN PEOPLE WITH THE MOST COMMON CF MUTATION, DELTA F508. CFFT HAS A UNIQUE AND SUCCESSFUL APPROACH TO SEEKING THE DEVELOPMENT OF DRUGS FOR A RARE DISEASE. THIS DRUG DEVELOPMENT MODEL HAS HELPED CREATE A PIPELINE THAT AT THE END OF 2011 HAD NEARLY 30 PROMISING DRUGS TO FIGHT CYSTIC FIBROSIS.Description

Activity2 Activity2

FieldValueIRS element (for citing)
Expense29724286Expense
Grants27991951Grants
Revenue551511Revenue
DescriptionMedical Programs in 2011 consisted of costs to support scientific study and investigations. 144 grants were awarded in 2011.Description
FieldValueIRS element (for citing)
Total Of Other Program Service Exp0TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt0TotalOfOtherProgramServiceGrnt
Total Of Other Program Service Rev0TotalOfOtherProgramServiceRev
Total Program Service Expense50139902TotalProgramServiceExpense
Described In501 C3trueDescribedIn501C3
Schedule B RequiredtrueScheduleBRequired
Political ActivitiesfalsePoliticalActivities
Lobbying ActivitiesfalseLobbyingActivities
Donor Advised FundsfalseDonorAdvisedFunds
Conservation EasementsfalseConservationEasements
Collections Of ArtfalseCollectionsOfArt
Credit CounselingfalseCreditCounseling
Term Or Permanent EndowmentsfalseTermOrPermanentEndowments
Report Land Bldg EquiptrueReportLandBldgEquip
Report Invest Oth SecuritiesfalseReportInvestOthSecurities
Report Prog Rel InvestfalseReportProgRelInvest
Report Other AssetstrueReportOtherAssets
Report Other LiabilitiesfalseReportOtherLiabilities
Report Fin48 FootnotefalseReportFin48Footnote
Independent Audit Financial StmtfalseIndependentAuditFinancialStmt
Consolidated Audit Financial StmttrueConsolidatedAuditFinancialStmt
SchoolfalseSchool
Foreign OfficefalseForeignOffice
Foreign ActivitiestrueForeignActivities
More Than5000 K To OrganizationstrueMoreThan5000KToOrganizations
More Than5000 K To IndividualsfalseMoreThan5000KToIndividuals
Professional FundraisingfalseProfessionalFundraising
Fundraising ActivitiesfalseFundraisingActivities
GamingfalseGaming
HospitalfalseHospital
Grants To OrganizationstrueGrantsToOrganizations
Grants To IndividualsfalseGrantsToIndividuals
Schedule J RequiredtrueScheduleJRequired
Tax Exempt BondsfalseTaxExemptBonds
Excess Benefit TransactionfalseExcessBenefitTransaction
Prior Excess Benefit TransactionfalsePriorExcessBenefitTransaction
Loan To Officer Or DQPfalseLoanToOfficerOrDQP
Grant To Related PersonfalseGrantToRelatedPerson
Bsnss Rltnshp With OrganizationfalseBsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family MemberfalseBsnssRltnshpThruFamilyMember
Officer Entity With Bsnss RltnshpfalseOfficerEntityWithBsnssRltnshp
Deductible Non Cash ContributionsfalseDeductibleNonCashContributions
Deductible Contributions Of ArtfalseDeductibleContributionsOfArt
TerminatedfalseTerminated
Partial LiquidationfalsePartialLiquidation
Disregarded EntityfalseDisregardedEntity
Related EntitytrueRelatedEntity
Related Org Controlled EntityfalseRelatedOrgControlledEntity
Transaction Related EntityfalseTransactionRelatedEntity
Transfers To Exempt Non Chrtbl OrgfalseTransfersToExemptNonChrtblOrg
Activities Conducted PartnershipfalseActivitiesConductedPartnership
Schedule O RequiredtrueScheduleORequired
Number Forms Transmitted With109670NumberFormsTransmittedWith1096
Number W2 G Included0NumberW2GIncluded
Number Of Employees12NumberOfEmployees
Employment Tax Returns FiledtrueEmploymentTaxReturnsFiled
Unrelated Business IncomefalseUnrelatedBusinessIncome
Foreign Financial AccountfalseForeignFinancialAccount
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTrans
Taxable Party NotificationfalseTaxablePartyNotification
Non Deductible ContributionsfalseNonDeductibleContributions
Quid Pro Quo ContributionsfalseQuidProQuoContributions
Form8282 Property Disposed OffalseForm8282PropertyDisposedOf
Funds To Pay PremiumsfalseFundsToPayPremiums
Premiums PaidfalsePremiumsPaid
Indoor Tanning ServicesfalseIndoorTanningServices
Info In Schedule O Part VIXInfoInScheduleOPartVI
Nbr Voting Governing Body Members7NbrVotingGoverningBodyMembers
Number Independent Voting Members6NumberIndependentVotingMembers
Family Or Business RelationshipfalseFamilyOrBusinessRelationship
Delegation Of Management DutiesfalseDelegationOfManagementDuties
Changes To Organizing DocsfalseChangesToOrganizingDocs
Material Diversion Or MisusefalseMaterialDiversionOrMisuse
Members Or StockholdersfalseMembersOrStockholders
Election Of Board MemberstrueElectionOfBoardMembers
Decisions Subject To ApprovalfalseDecisionsSubjectToApproval
Minutes Of Governing BodytrueMinutesOfGoverningBody
Minutes Of CommitteestrueMinutesOfCommittees
Officer Mailing AddressfalseOfficerMailingAddress
Local ChaptersfalseLocalChapters
Form990 Provided To Governing BodytrueForm990ProvidedToGoverningBody
Conflict Of Interest PolicytrueConflictOfInterestPolicy
Annual Disclosure Covered PersonstrueAnnualDisclosureCoveredPersons
Regular Monitoring EnforcementtrueRegularMonitoringEnforcement
Whistleblower PolicytrueWhistleblowerPolicy
Document Retention PolicytrueDocumentRetentionPolicy
Compensation Process CEOtrueCompensationProcessCEO
Compensation Process OthertrueCompensationProcessOther
Investment In Joint VenturefalseInvestmentInJointVenture
Own WebsiteXOwnWebsite
Upon RequestXUponRequest

The Books Are In Care Of TheBooksAreInCareOf

FieldValueIRS element (for citing)
Name PersonROBERT J BEALL PHDNamePerson
Telephone Number3019514422TelephoneNumber

Address US AddressUS

FieldValueIRS element (for citing)
Address Line16931 ARLINGTON ROAD STE 200AddressLine1
CityBETHESDACity
StateMDState
ZIP Code20814ZIPCode
FieldValueIRS element (for citing)
Info In Schedule O Part VIIXInfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (14 entries)

TitleTitleAverage Hours Per WeekAverageHoursPerWeekIndividual Trustee Or DirectorIndividualTrusteeOrDirectorReportable Comp From OrganizationReportableCompFromOrganizationReportable Comp From Related OrgsReportableCompFromRelatedOrgsOther CompensationOtherCompensationOfficerOfficerKey EmployeeKeyEmployeeHighest Compensated EmployeeHighestCompensatedEmployee
Theodore J Torphy PhD
CHAIRMAN5.0X000
STEVEN SHAK MD
DIRECTOR3.0X000
CATHERINE C MCLOUD
DIRECTOR3.0X000
JONATHAN COHN MD
director3.0X000
JASON M ARYEH
DIRECTOR3.0X000
D PAUL FLESSNER
director3.0X000
Robert J Beall PhD
President & CEO18.0X234488477065362172X
Preston W Campbell MD
Exec VP of Medical Affairs18.0156360310778268893X
C Richard Mattingly
Exec VP and COO5.00475320284459X
Vera H Twigg
Sr. VP and CFO5.00325228119955X
BRUCE MARSHALL MD
VP OF CLINICAL AFFAIRS50.0339453026029X
CYNTHIA GEORGE MSN FNP BC
DIR OF CLINICAL RES RESOURCES50.0111524015333X
MARTIN MENSE
PRINCIPAL SCIENTIST DRUG DISC50.0161275043814X
ELIZABETH JOSELOFF PHD
INTEGRATIVE BIOLOGY DIRECTOR50.0103125027904X
FieldValueIRS element (for citing)
Total Reportable Comp From Org1106225TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs1588391TotalReportableCompFrmRltdOrgs
Total Other Compensation1148559TotalOtherCompensation
Number Individuals GT100 K6NumberIndividualsGT100K
Formers ListedfalseFormersListed
Total Comp GT150 KtrueTotalCompGT150K
Compensation From Other SourcesfalseCompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1CityAddressOfContractor/AddressUS/CityStateAddressOfContractor/AddressUS/StateZIP CodeAddressOfContractor/AddressUS/ZIPCodeDescription Of ServicesDescriptionOfServicesCompensationCompensation
VERTEX PHARMACEUTICALS LLC
130 WAVERLY STREETCAMBRIDGEMA02139CONTRACTED RESEARCH9222356
CHANTEST INC
14556 NEO PARKWAYCLEVELANDOH44128RESEARCH SUPPORT2275000
PFIZER INC
100 ACORN PARK DRIVECAMBRIDGEMA02140CONTRACTED RESEARCH3125718
OUTCOME SCIENCES INC
PO BOX 983022BOSTONMA022983022CLINICAL RESEARCH433655
SCHANER LUBITZ PLLC
6931 ARLINGTON ROAD SUITE 200BETHESDAMD20814LEGAL SERVICES261943
FieldValueIRS element (for citing)
Number Of Contractors GT100 K5NumberOfContractorsGT100K
Related Organizations49932523RelatedOrganizations
All Other Contributions49932523AllOtherContributions
Total Contributions99865046TotalContributions

Program Service Revenue ProgramServiceRevenue (2 entries)

DescriptionDescriptionBusiness CodeBusinessCodeTotal Revenue ColumnTotalRevenueColumnRelated Or Exempt Function IncomeRelatedOrExemptFunctionIncome
CLINICAL STUDY541900222000222000
REFUNDED OR CANCELLED GRANTS900099329511329511
FieldValueIRS element (for citing)
Total Program Service Revenue551511TotalProgramServiceRevenue

Investment Income InvestmentIncome

FieldValueIRS element (for citing)
Total Revenue Column188TotalRevenueColumn
Exclusion$188ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

FieldValueIRS element (for citing)
Total Revenue Column4013TotalRevenueColumn
Exclusion$4,013ExclusionAmount

Net Gain Or Loss Investments NetGainOrLossInvestments

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income Or Loss NetIncomeOrLoss

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn
FieldValueIRS element (for citing)
Total Other Revenue0TotalOtherRevenue

Total Revenue TotalRevenue

FieldValueIRS element (for citing)
Total Revenue Column100420758TotalRevenueColumn
Related Or Exempt Function Income551511RelatedOrExemptFunctionIncome
Exclusion$4,201ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

FieldValueIRS element (for citing)
Total26106741Total
Program Services26106741ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

FieldValueIRS element (for citing)
Total3399Total
Program Services3399ProgramServices

Foreign Grants ForeignGrants

FieldValueIRS element (for citing)
Total1881811Total
Program Services1881811ProgramServices

Benefits To Members BenefitsToMembers

FieldValueIRS element (for citing)
Total0Total

Comp Current Officers Directors CompCurrentOfficersDirectors

FieldValueIRS element (for citing)
Total390848Total
Program Services355302ProgramServices
Management And General35546ManagementAndGeneral
Fundraising0Fundraising

Comp Disqual Persons CompDisqualPersons

FieldValueIRS element (for citing)
Total0Total

Other Salaries And Wages OtherSalariesAndWages

FieldValueIRS element (for citing)
Total2150172Total
Program Services1954623ProgramServices
Management And General195549ManagementAndGeneral
Fundraising0Fundraising

Pension Plan Contributions PensionPlanContributions

FieldValueIRS element (for citing)
Total112997Total
Program Services102720ProgramServices
Management And General10277ManagementAndGeneral
Fundraising0Fundraising

Other Employee Benefits OtherEmployeeBenefits

FieldValueIRS element (for citing)
Total210588Total
Program Services191436ProgramServices
Management And General19152ManagementAndGeneral
Fundraising0Fundraising

Payroll Taxes PayrollTaxes

FieldValueIRS element (for citing)
Total143800Total
Program Services129760ProgramServices
Management And General14040ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Management FeesForServicesManagement

FieldValueIRS element (for citing)
Total0Total
Program Services0ProgramServices
Management And General0ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Legal FeesForServicesLegal

FieldValueIRS element (for citing)
Total261943Total
Program Services261943ProgramServices
Management And General0ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Accounting FeesForServicesAccounting

FieldValueIRS element (for citing)
Total4790Total
Program Services0ProgramServices
Management And General4790ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Lobbying FeesForServicesLobbying

FieldValueIRS element (for citing)
Total0Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total0Total

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

FieldValueIRS element (for citing)
Total0Total

Fees For Services Other FeesForServicesOther

FieldValueIRS element (for citing)
Total3705Total
Program Services0ProgramServices
Management And General3705ManagementAndGeneral
Fundraising0Fundraising

Advertising Advertising

FieldValueIRS element (for citing)
Total0Total

Office Expenses OfficeExpenses

FieldValueIRS element (for citing)
Total180560Total
Program Services163062ProgramServices
Management And General17498ManagementAndGeneral
Fundraising0Fundraising

Information Technology InformationTechnology

FieldValueIRS element (for citing)
Total319734Total
Program Services303417ProgramServices
Management And General16317ManagementAndGeneral
Fundraising0Fundraising

Royalties Royalties

FieldValueIRS element (for citing)
Total0Total

Occupancy Occupancy

FieldValueIRS element (for citing)
Total204557Total
Program Services183530ProgramServices
Management And General21027ManagementAndGeneral
Fundraising0Fundraising

Travel Travel

FieldValueIRS element (for citing)
Total78786Total
Program Services74058ProgramServices
Management And General4728ManagementAndGeneral
Fundraising0Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

FieldValueIRS element (for citing)
Total0Total

Conferences Meetings ConferencesMeetings

FieldValueIRS element (for citing)
Total57270Total
Program Services56020ProgramServices
Management And General1250ManagementAndGeneral
Fundraising0Fundraising

Interest Interest

FieldValueIRS element (for citing)
Total0Total

Payments To Affiliates PaymentsToAffiliates

FieldValueIRS element (for citing)
Total0Total

Depreciation Depletion DepreciationDepletion

FieldValueIRS element (for citing)
Total63346Total
Program Services60621ProgramServices
Management And General2725ManagementAndGeneral
Fundraising0Fundraising

Insurance Insurance

FieldValueIRS element (for citing)
Total141709Total
Program Services141709ProgramServices
Management And General0ManagementAndGeneral
Fundraising0Fundraising

Other Expenses OtherExpenses (3 entries)

DescriptionDescriptionTotalTotalProgram ServicesProgramServicesManagement And GeneralManagementAndGeneralFundraisingFundraising
CONTRACTED RESEARCH179165531791655300
CHEMISTRY25200025200000
MISCELLANEOUS292611971729

Total Functional Expenses TotalFunctionalExpenses

FieldValueIRS element (for citing)
Total50488235Total
Program Services50139902ProgramServices
Management And General348333ManagementAndGeneral
Fundraising0Fundraising

Cash Non Interest Bearing CashNonInterestBearing

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

FieldValueIRS element (for citing)
BOY1068631BOY
EOY3733071EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Accounts Receivable AccountsReceivable

FieldValueIRS element (for citing)
BOY66488635BOY
EOY2249263EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

FieldValueIRS element (for citing)
BOY32500BOY
EOY229498EOY
FieldValueIRS element (for citing)
Land Buildings Equipment Basis445281LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec287872LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

FieldValueIRS element (for citing)
BOY49859BOY
EOY157409EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Investments Other Securities InvestmentsOtherSecurities

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Investments Program Related InvestmentsProgramRelated

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Intangible Assets IntangibleAssets

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Other Assets Total OtherAssetsTotal

FieldValueIRS element (for citing)
BOY0BOY
EOY21763924EOY

Total Assets TotalAssets

FieldValueIRS element (for citing)
BOY67639625BOY
EOY28133165EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

FieldValueIRS element (for citing)
BOY16758245BOY
EOY989715EOY

Grants Payable GrantsPayable

FieldValueIRS element (for citing)
BOY22749014BOY
EOY27143450EOY

Deferred Revenue DeferredRevenue

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Escrow Account Liability EscrowAccountLiability

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Loans From Officers Directors LoansFromOfficersDirectors

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Other Liabilities OtherLiabilities

FieldValueIRS element (for citing)
BOY28132366BOY
EOY0EOY

Total Liabilities TotalLiabilities

FieldValueIRS element (for citing)
BOY67639625BOY
EOY28133165EOY
FieldValueIRS element (for citing)
Follow SFAS117XFollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY0BOY
EOY0EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY67639625BOY
EOY28133165EOY
FieldValueIRS element (for citing)
Info In Schedule O Part XIXInfoInScheduleOPartXI
Reconcilation Revenue Expenses49932523ReconcilationRevenueExpenses
Reconcilation Other Changes-49932523ReconcilationOtherChanges
Method Of Accounting AccrualXMethodOfAccountingAccrual
Accountant Compile Or ReviewfalseAccountantCompileOrReview
FS AuditedtrueFSAudited
Audit CommitteetrueAuditCommittee
Financial Statement ConsolidatedXFinancialStatementConsolidated
Federal Grant Audit RequiredfalseFederalGrantAuditRequired

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Supporting Organization509a3XSupportingOrganization509a3
Supporting Org509a3 Type1XSupportingOrg509a3Type1
Certification CheckboxXCertificationCheckbox
Contrib By Controlling IndividualfalseContribByControllingIndividual
Contribution By Related PartyfalseContributionByRelatedParty
Contrib By35 Controlled EntityfalseContribBy35ControlledEntity

Supported Org Information SupportedOrgInformation

Name Name

FieldValueIRS element (for citing)
Business Name Line1CYSTIC FIBROSIS FOUNDATIONBusinessNameLine1
FieldValueIRS element (for citing)
EIN131930701EIN
Type Of Organization03TypeOfOrganization
Listed In Governing DoctrueListedInGoverningDoc
Supported Organization NotifiedtrueSupportedOrganizationNotified
Organized In UStrueOrganizedInUS
Amount$0Amount
FieldValueIRS element (for citing)
Total Number Of Supported Orgs1TotalNumberOfSupportedOrgs
Sum Of Amounts0SumOfAmounts

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

FieldValueIRS element (for citing)
Contributor NumberRESTRICTEDContributorNumber

Contributor Name Business ContributorNameBusiness

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor Address US ContributorAddressUS

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Aggregate ContributionsRESTRICTEDAggregateContributions

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Art Public Exhibition AmtsArtPublicExhibitionAmts
Held Works Of Art AmtsHeldWorksOfArtAmts
Current Year Minus3 YearsCurrentYearMinus3Years
LandLand
BuildingsBuildings
Leasehold ImprovementsLeaseholdImprovements

Equipment Equipment

FieldValueIRS element (for citing)
Other Cost Or Other Basis445281OtherCostOrOtherBasis
Depreciation287872Depreciation
Book Value157409BookValue
FieldValueIRS element (for citing)
Other Land BuildingsOtherLandBuildings
Total Of Book Value Land Buildings157409TotalOfBookValueLandBuildings

Other Assets OtherAssets

FieldValueIRS element (for citing)
DescriptionINTERCOMPANY RECEIVABLEDescription
Book Value21763924BookValue
FieldValueIRS element (for citing)
Total Book Value Other Assets21763924TotalBookValueOtherAssets

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedtrueGrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (4 entries)

RegionRegionType Of Activities ConductedTypeOfActivitiesConductedSpecific Services ProvidedSpecificServicesProvidedTotal ExpendituresTotalExpenditures
North AmericaGrantmakingNONE744001
Europe (Including Iceland and Greenland)GrantmakingNONE1004812
East Asia and the PacificGrantmakingNONE50000
Middle East and North AfricaGrantmakingNONE82998
FieldValueIRS element (for citing)
Subtotal Amount Spent1881811SubtotalAmountSpent
Total Amount Spent1881811TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (13 entries)

RegionRegionPurpose Of GrantPurposeOfGrantAmount Of Cash GrantAmountOfCashGrantManner Of Cash DisbursementMannerOfCashDisbursement
North AmericaCLINICAL RESEARCH166571CHECK
North AmericaDRUG DISCOVERY216000CHECK
North AmericaDRUG DISCOVERY262660CHECK
North AmericaDRUG DISCOVERY98770CHECK
Europe/Iceland/GreenlandCLINICAL RESEARCH58000WIRE
Europe/Iceland/GreenlandCLINICAL RESEARCH230585WIRE
Europe/Iceland/GreenlandCLINICAL RESEARCH18051WIRE
Europe/Iceland/GreenlandDRUG DISCOVERY151297WIRE
Europe/Iceland/GreenlandDRUG DISCOVERY277952WIRE
Europe/Iceland/GreenlandDRUG DISCOVERY168927CHECK
Europe/Iceland/GreenlandDRUG DISCOVERY100000WIRE
East Asia/PacificCLINICAL RESEARCH50000WIRE
Middle East/North AfricaDRUG DISCOVERY82998WIRE
FieldValueIRS element (for citing)
Total Number Of501c3 Orgs12TotalNumberOf501c3Orgs
Transfer To Foreign CorpfalseTransferToForeignCorp
Interest In Foreign TrustfalseInterestInForeignTrust
Own Foreign CorpfalseOwnForeignCorp
Passive Foreign Invest CofalsePassiveForeignInvestCo
Foreign PartnershipfalseForeignPartnership
Boycott CountriesfalseBoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

FieldValueIRS element (for citing)
IdentifierProcedures for monitoring grant funds outside of the U.S.Identifier
Return ReferenceSchedule F, Part I, Line 2ReturnReference
ExplanationTHE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANTS AWARDED TO ENTITIES OUTSIDE OF THE UNITED STATES. THE ORGANIZATION FOLLOWS THE U.S. DEPARTMENT OF TREASURY ANTI-TERRORIST FINANCING VOLUNTARY BEST PRACTICES GUIDELINES FOR CHARITIES. IN COMPLIANCE WITH THE BEST PRACTICES, THE ORGANIZATION COLLECTS AND REVIEWS INFORMATION ABOUT THE PROSPECTIVE GRANTEES AND CONDUCTS A VETTING PROCESS TO ENSURE THEY ARE NOT SUSPECTED OF ACTIVITIES RELATED TO TERRORISM. ONCE A GRANT IS APPROVED, A WRITTEN AGREEMENT IS SIGNED BY BOTH THE ORGANIZATION AND THE GRANTEE. FUNDING IS INCREMENTAL AND SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO DETERMINE PROGRESS. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS. THE GRANT IN THE MIDDLE EAST/NORTH AFRICA REGION WAS MADE TO A UNIVERSITY IN ISRAEL.Explanation

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Records MaintainedtrueRecordsMaintained

Recipient Table RecipientTable (128 entries)

Address Line1AddressUS/AddressLine1Address Line2AddressUS/AddressLine2CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEIN Of RecipientEINOfRecipientIRC SectionIRCSectionAmount Of Cash GrantAmountOfCashGrantPurpose Of GrantPurposeOfGrant
Albany Medical College
47 New Scotland AveMail Code 88AlbanyNY12208141338310501c(3)74088CLINICAL RESEARCH STUDY
All Children's Hospital
Dept 9010PO Box 31020St PetersburgFL33731590683252501c(3)80438CLINICAL RESEARCH STUDY
Arizona Board of Regents University of Arizona
Sponsored Projects Services888 N Euclid Room 510TucsonAZ85722742652689501c(3)134938CLINICAL RESEARCH AWARDS
Arizona Board of Regents University of Arizona
Sponsored Projects Services888 N Euclid Room 510TucsonAZ85722742652689501c(3)71217CLINICAL RESEARCH STUDY
Baylor College of Medicine
PO Box 1HoustonTX77212741613878501c(3)98537CLINICAL RESEARCH STUDY
Beth Israel Medical Center
Office of Grants ContractsNew YorkNY10038135564934501c(3)74088CLINICAL RESEARCH STUDY
Case Western Reserve University
10900 Euclid Avenue160 Water Street 24th FloorClevelandOH441067015341018992501c(3)261084CLINICAL RESEARCH STUDY
Case Western Reserve University
10900 Euclid AvenueClevelandOH441067015341018992501c(3)169525PHASE III TRIALS
Case Western Reserve University
10900 Euclid AvenueSuite 208ClevelandOH441067015341018992501c(3)137362CLINICAL RESEARCH AWARDS
Children's & Women's Physicians of Westchester LL
Pediatrics DepartmentMunger Pavilion Room 123ValhallaNY10595133940462501c(3)68976CLINICAL RESEARCH STUDY
Children's Health Care
2525 Chicago Avenue SouthMunger Pavilion Room 123MinneapolisMN554041844411754276501c(3)63504CLINICAL RESEARCH STUDY
Children's Hospital Corporation
300 Longwood AvenueBostonMA02115042774441501c(3)98537CLINICAL RESEARCH STUDY
Children's Hospital Corporation
300 Longwood AvenueBostonMA02115042774441501c(3)68250CLINICAL RESEARCH AWARDS
Children's Hospital Medical Center of Akron
1 Perkins SquareAkronOH44308340714357501c(3)80438CLINICAL RESEARCH STUDY
Children's Hospital Medical Center Cincinnati
3333 Burnet AvenueCincinnatiOH45229310833936501c(3)260406CLINICAL RESEARCH STUDY
Children's Hospital Medical Center Cincinnati
3333 Burnet AvenueCincinnatiOH45229310833936501c(3)135386CLINICAL RESEARCH AWARDS
Children's Hospital Medical Center Cincinnati
3333 Burnet AvenueCincinnatiOH45229310833936501c(3)25612ACADEMIC ADVISORY AWARDS
Children's Medical Center
One Childrens PlazaDaytonOH45404310672132501c(3)68976CLINICAL RESEARCH STUDY
Children's Memorial Hospital
2300 Childrens PlazaChicagoIL60614363357006501c(3)172800CLINICAL RESEARCH STUDY
Connecticut Children's Medical Center
282 Washington StreetBox 43HartfordCT06106060646755501c(3)78830CLINICAL RESEARCH STUDY
Cook Children's Medical Center
801 Seventh AvenueFt WorthTX76104752051646501c(3)66864CLINICAL RESEARCH STUDY
Drexel University College of Medicine
Erie Ave at Front StPhiladelphiaPA191291192232979433501c(3)76416CLINICAL RESEARCH STUDY
Duke University Medical Center
Box 3001Suite 2215DurhamNC27710560532129501c(3)59736CLINICAL RESEARCH STUDY
Emory University
1784 N Decatur RoadAtlantaGA30322580566256501c(3)298646CLINICAL RESEARCH AWARDS
Emory University
1784 N Decatur RoadSuite 510AtlantaGA30322580566256501c(3)93887CLINICAL RESEARCH STUDY
Kaiser Foundation Research Institute
1800 Harrison StreetSuite 510OaklandCA94612941105628501c(3)59122CLINICAL RESEARCH STUDY
Maine Medical Center
22 Bramhall Street16th FloorPortlandME041023175010238552501c(3)227276CLINICAL RESEARCH AWARDS
Maine Medical Center
22 Bramhall StreetPortlandME041023175010238552501c(3)66206CLINICAL RESEARCH STUDY
Medical University of South Carolina
PO Box 997CharlestonSC29402576000722501c(3)84672CLINICAL RESEARCH STUDY
Monmouth Medical Center Foundation
300 Second AvenueLong BranchNJ07740222456079501c(3)74088CLINICAL RESEARCH STUDY
National Jewish Medical and Research Center
1400 Jackson StreetDenverCO80206742044647501c(3)123374CLINICAL RESEARCH AWARDS
Nemours Children's Clinic - Jacksonville
807 Nira StreetJacksonvilleFL32207590634433501c(3)174554CLINICAL RESEARCH STUDY
Oregon Health & Science University
Sponsored Projects Administration OPortlandOR97239237083114501c(3)270000DRUG DISCOVERY AWARDS
Oregon Health & Sciences University
3181 SW Sam Jackson Park Road0690 SW Bancroft StreetPortlandOR97201237083114501c(3)80438CLINICAL RESEARCH STUDY
Pennsylvania State University
College of MedicineL-106HersheyPA17033246000376501c(3)80438CLINICAL RESEARCH STUDY
Phoenix Children's Hospital
1300 North 12th StreetOffice of Research Affairs H138PhoenixAZ85006860422559501c(3)68976CLINICAL RESEARCH STUDY
Providence Alaska Medical Center
4045 Lake Otis Pkwy 209AnchorageAK99508920016429501c(3)63504CLINICAL RESEARCH STUDY
Regents of the University of Colorado
Grants Contracts13123 East 16th Avenue B395AuroraCO800450508846000555501c(3)9767ACADEMIC ADVISORY AWARDS
Regents of the University of Colorado at Denver
Grants and Contracts Mail Stop F42F428 Fitzsimons Building 500AuroraCO80045846000555501c(3)61358PHASE III TRIALS
Regents of the University of Colorado at Denver
Grants and Contracts Mail Stop F42Anschutz Medical Campus Bldg 500AuroraCO80045846000555501c(3)26839CLINICAL RESEARCH AWARDS
Regents of the University of Colorado at Denver an
The Childrens HospitalAnschutz Medical Campus Bldg 500AuroraCO80045846000555501c(3)146088CLINICAL RESEARCH STUDY
Research Foundation of SUNY on behalf of Univ at
402 Crofts Hall13123 East 16th Avenue B395BuffaloNY142607016141368361501c(3)28728CLINICAL RESEARCH AWARDS
Research Foundation of SUNY on behalf of Upstate M
PO Box 9University at BuffaloAlbanyNY122010009141368361501c(3)84625CLINICAL RESEARCH STUDY
Rosalind Franklin University of Medicine and Scien
Green Bay RoadNorth ChicagoIL60064362181973501c(3)808261DRUG DISCOVERY AWARDS
Sanford Childrens Specialty Clinic
1305 W 18th StreetSioux FallsSD57117460447693501c(3)60329CLINICAL RESEARCH STUDY
Seattle Children's Hospital
4800 Sand Point Way NESeattleWA98105910564748501c(3)4093054CLINICAL RESEARCH STUDY
Seattle Children's Hospital
4800 Sand Point Way NESeattleWA98105910564748501c(3)3133321PHASE III TRIALS
Seattle Children's Hospital
4800 Sand Point Way NESeattleWA98105910564748501c(3)463732CLINICAL RESEARCH AWARDS
Seton Healthcare
4900 Mueller BlvdAustinTX78723741109643501c(3)80438CLINICAL RESEARCH STUDY
Spectrum Health
Downtown CampusDCMC Administration 3rd FloorGrand RapidsMI49503382752328501c(3)66864CLINICAL RESEARCH STUDY
St Louis University
3500 Lindell Blvd100 Michigan Street NESt LouisMO63103430654872501c(3)70384CLINICAL RESEARCH STUDY
St Luke's Regional Medical Center
100 East IdahoBoiseID83712820161600501c(3)63504CLINICAL RESEARCH STUDY
Stanford University
651 Serra Street Suite 220Suite 200StanfordCA943056215941156365501c(3)171687CLINICAL RESEARCH STUDY
Stanford University
651 Serra Street Suite 220Mail Code 5402StanfordCA943056215941156365501c(3)167447CLINICAL RESEARCH AWARDS
Texas Tech University Health Sciences Center
3601 4th Street Stop 6540Mail Code 5402LubbockTX79430752668014501c(3)151903DRUG DISCOVERY AWARDS
The Children's Hospital Association
13123 East 16th Avenue B321MC0831AuroraCO80045840166760501c(3)382825CLINICAL RESEARCH AWARDS
The Children's Hospital Association
13123 East 16th Avenue B321Room 1044AuroraCO80045840166760501c(3)172800CLINICAL RESEARCH STUDY
The Children's Hospital of Philadelphia
34th and Civic Center BoulevardRoom 1044PhiladelphiaPA19104231352166501c(3)94772CLINICAL RESEARCH STUDY
The Children's Mercy Hospital
2401 Gillham Road200 Oak Street SE Suite 450Kansas CityMO61408440605373501c(3)80438CLINICAL RESEARCH STUDY
The Feinstein Institute for Medical Research
350 Community DriveManhassetNY11030112673595501c(3)80438CLINICAL RESEARCH STUDY
The General Hospital Corporation (aka Massachuse
PO Box 414876BostonMA022414876042697983501c(3)85729DRUG DISCOVERY AWARDS
The General Hospital Corporation (aka Massachuse
55 Fruit StreetGeneral Post OfficeBostonMA02114042697983501c(3)80438CLINICAL RESEARCH STUDY
The Johns Hopkins University
600 N Wolfe Street Park 316General Post OfficeBaltimoreMD21205520595110501c(3)608417CLINICAL RESEARCH AWARDS
The Johns Hopkins University
600 N Wolfe Street Park 316BaltimoreMD21205520595110501c(3)361130DRUG DISCOVERY AWARDS
The Johns Hopkins University
600 N Wolfe Street Park 316BaltimoreMD21205520595110501c(3)197700CLINICAL RESEARCH STUDY
The Johns Hopkins University
600 N Wolfe Street Park 316Suite 620 ACCBaltimoreMD21205520595110501c(3)154910PHASE III TRIALS
The Johns Hopkins University
600 N Wolfe Street Park 316Suite 620 ACCBaltimoreMD21205520595110501c(3)24752ACADEMIC ADVISORY AWARDS
The Medical College of Wisconsin
8701 Watertown Plk Rd970 E 58th StreetMilwaukeeWI53226390806261501c(3)75937CLINICAL RESEARCH STUDY
The Rector and Visitors of the University of Virgi
Office of Sponsored ProgramsCharlottesvilleVA229044195546001796501c(3)84658CLINICAL RESEARCH STUDY
The Regents of the University of California San D
9500 Gilman DrPO Box 400195La JollaCA920930984956006144501c(3)107787DRUG DISCOVERY AWARDS
The Regents of the University of California San D
9500 Gilman DrMC0954La JollaCA920930984956006144501c(3)63079CLINICAL RESEARCH STUDY
The Regents of the University of California San D
9500 Gilman DrMC0954La JollaCA920930984956006144501c(3)62681CLINICAL RESEARCH AWARDS
The Regents of The University of Michigan
3003 South State StreetMC 0954Ann ArborMI481091274386006309501c(3)379907CLINICAL RESEARCH AWARDS
The Regents of The University of Michigan
3003 South State StreetRoom 1044Ann ArborMI481091274386006309501c(3)100548CLINICAL RESEARCH STUDY
The Regents of the University of Minnesota
Sponsored Projects AdministrationRoom 1044MinneapolisMN554552070416007513501c(3)167922CLINICAL RESEARCH STUDY
The Regents of the University of Minnesota
Sponsored Projects Administration200 Oak Street SE Suite 450MinneapolisMN554552070416007513501c(3)68250CLINICAL RESEARCH AWARDS
The Research Institute at Nationwide Children's Ho
700 Childrens Drive200 Oak Street SE Suite 450ColumbusOH43205316056230501c(3)108754CLINICAL RESEARCH STUDY
The Research Institute at Nationwide Children's Ho
700 Childrens DriveColumbusOH43205316056230501c(3)37594DRUG DISCOVERY AWARDS
The Scripps Research Institute
10666 North Torrey Pines RoadLa JollaCA92037330435954501c(3)504000DRUG DISCOVERY AWARDS
The Toledo Hospital
2142 N Cove BlvdToledoOH43606344428256501c(3)84672CLINICAL RESEARCH STUDY
The Trustees of Columbia University in the City of
PO Box 29789New YorkNY100879789135598093501c(3)123240DRUG DISCOVERY AWARDS
The Trustees of Columbia University in the City of
PO Box 29789General Post OfficeNew YorkNY100879789135598093501c(3)62855CLINICAL RESEARCH STUDY
The Trustees of Columbia University in the City of
PO Box 29789General Post OfficeNew YorkNY100879789135598093501c(3)23906ACADEMIC ADVISORY AWARDS
The University of Alabama at Birmingham
1600 7th Avenue SouthGeneral Post OfficeBirminghamAL35233636005396501c(3)1118746DRUG DISCOVERY AWARDS
The University of Alabama at Birmingham
1600 7th Avenue SouthSuite 620 ACCBirminghamAL35233636005396501c(3)408121CLINICAL RESEARCH STUDY
The University of Alabama at Birmingham
1600 7th Avenue SouthSuite 620 ACCBirminghamAL35233636005396501c(3)56851ACADEMIC ADVISORY AWARDS
The University of Alabama at Birmingham
1600 7th Avenue SouthSuite 620 ACCBirminghamAL35233636005396501c(3)23792PHASE III TRIALS
The University of Chicago
University Research AdministrationSuite 620 ACCChicagoIL60637362177139501c(3)59122CLINICAL RESEARCH STUDY
The University of Chicago
University Research Administration970 E 58th StreetChicagoIL60637362177139501c(3)30366ACADEMIC ADVISORY AWARDS
The University of Iowa
Office of Vice President for Resear970 E 58th StreetIowa CityIA52242426004813501c(3)400468DRUG DISCOVERY AWARDS
The University of Iowa
Office of Vice President for ResearDivision of Sponsored ProgramsIowa CityIA52242426004813501c(3)172800CLINICAL RESEARCH STUDY
The University of North Carolina at Chapel Hill
300 Bynum HallDivision of Sponsored ProgramsChapel HillNC275994100566001393501c(3)1064941DRUG DISCOVERY AWARDS
The University of North Carolina at Chapel Hill
300 Bynum HallCB 4100Chapel HillNC275994100566001393501c(3)797722PHASE III TRIALS
The University of North Carolina at Chapel Hill
300 Bynum HallCB 4100Chapel HillNC275994100566001393501c(3)294955CLINICAL RESEARCH STUDY
The University of North Carolina at Chapel Hill
300 Bynum HallCB 4100Chapel HillNC275994100566001393501c(3)204637CLINICAL RESEARCH AWARDS
The University of Utah
201 S Presidents CircleCB 4100Salt Lake CityUT84112876000525501c(3)100436CLINICAL RESEARCH STUDY
The University of Vermont and State Agricultural C
Grant and Contract Administrative SRoom 406BurlingtonVT05405030179440501c(3)80438CLINICAL RESEARCH STUDY
Trustee of Indiana University
Financial Management Services223 Waterman BldgIndianapolisIN462666057356001673501c(3)100548CLINICAL RESEARCH STUDY
Trustees of Dartmouth College
Dartmouth Medical SchoolPO Box 66057HanoverNH037551404020222111501c(3)95211ACADEMIC ADVISORY AWARDS
University at Buffalo Pediatric Associates
239 Bryant StreetDept of Microbiology and ImmunologBuffaloNY14222161238821501c(3)128900ACADEMIC ADVISORY AWARDS
University at Buffalo Pediatric Associates
239 Bryant Street2nd FloorBuffaloNY14222161238821501c(3)84672CLINICAL RESEARCH STUDY
University of Arkansas for Medical Sciences
4301 West Markham Street2nd FloorLittle RockAR72205716046242501c(3)80438CLINICAL RESEARCH STUDY
University of Connecticut
Office of Sponsored ProgramsMail Slot 555StorrsCT062691133060772160501c(3)98600DRUG DISCOVERY AWARDS
University of Kentucky Research Foundation
337 Peterson438 Whitney Road Ext U-1133LexingtonKY405060005616033693501c(3)76416CLINICAL RESEARCH STUDY
University of Massachusetts Medical School
55 Lake Avenue NorthWorcesterMA01655043167352501c(3)57312CLINICAL RESEARCH STUDY
University of Miami
PO Box 025405MiamiFL331025405590624458501c(3)74088CLINICAL RESEARCH STUDY
University of Nebraska Medical Center
985100 Nebraska Medical CenterOmahaNE681985190470491233501c(3)80438CLINICAL RESEARCH STUDY
University of Oklahoma Health Sciences Center
PO Box 26901Oklahoma CityOK73190736017987501c(3)74088CLINICAL RESEARCH STUDY
University of Pittsburgh
350 Thackeray HallPittsburghPA15260250965591501c(3)422250DRUG DISCOVERY AWARDS
University of Pittsburgh
350 Thackeray HallPittsburghPA15260250965591501c(3)204598CLINICAL RESEARCH STUDY
University of Rochester
Box 649RochesterNY14642160743209501c(3)76416CLINICAL RESEARCH STUDY
University of South Alabama
Admin Bldg 362601 Elmwood AvenueMobileAL36688630477348501c(3)88932DRUG DISCOVERY AWARDS
University of Tennessee
62 S DunlapMemphisTN38163626001636501c(3)83589CLINICAL RESEARCH STUDY
University of Texas Health Science Center at San A
Office of Sponsored Programs MC 78San AntonioTX78229741586031501c(3)74088CLINICAL RESEARCH STUDY
University of Washington
Office of Sponsored Programs7703 Floyd Curl DriveSeattleWA981056692916001537501c(3)56961DRUG DISCOVERY AWARDS
University of Washington
Office of Sponsored Programs4333 Brooklyn Avenue NESeattleWA981056692916001537501c(3)32248CLINICAL RESEARCH AWARDS
University of Washington
Grant Contract Accounting4333 Brooklyn Avenue NESeattleWA981056692916001537501c(3)10996ACADEMIC ADVISORY AWARDS
University of Wisconsin Board of Regents
750 University Avenue3917 University Way NEMadisonWI53706396006492501c(3)84041CLINICAL RESEARCH AWARDS
University of Wisconsin Board of Regents
750 University AvenueMadisonWI53706396006492501c(3)70384CLINICAL RESEARCH STUDY
UT Southwestern Medical Center at Dallas
5323 Harry Hines BoulevardDallasTX753909105756002868501c(3)295939DRUG DISCOVERY AWARDS
UT Southwestern Medical Center at Dallas
5323 Harry Hines BoulevardDallasTX753909105756002868501c(3)80438CLINICAL RESEARCH STUDY
Vanderbilt University Medical Center
PO Box 30195NashvilleTN372410195620476822501c(3)76416CLINICAL RESEARCH STUDY
Via Christi Regional Medical Center Inc
707 N EmporiaWichitaKS67214481172106501c(3)60329CLINICAL RESEARCH STUDY
Virginia Commonwealth University
Box 2506 - VCU StationRichmondVA232842506546001758501c(3)80438CLINICAL RESEARCH STUDY
Washington University
660 S Euclid AvenueSt LouisMO63110430653611501c(3)80435CLINICAL RESEARCH STUDY
Wayne State University
Grants Contracts Office IIIDetroitMI48201383028425501c(3)78830CLINICAL RESEARCH STUDY
West Virginia University Research Corporation
WVUResearch and Sponsored ProgramsMorgantownWV265066001550665758501c(3)66864CLINICAL RESEARCH STUDY
Yale University
47 College Street Suite 203One Waterfront PlaceNew HavenCT065208047060646973501c(3)57312CLINICAL RESEARCH STUDY
FieldValueIRS element (for citing)
Total Nbr Of501 C3 And Govt Grants86TotalNbrOf501C3AndGovtGrants

Form990 Schedule I Part IV Form990ScheduleIPartIV

FieldValueIRS element (for citing)
IdentifierPROCEDURES FOR MONITORING GRANT FUNDS INSIDE OF THE U.S.Identifier
Return ReferencePART I, LINE 2ReturnReference
ExplanationTHE ORGANIZATION HAS PROCEDURES IN PLACE TO MONITOR THE SCIENTIFIC PROGRESS AND FINANCIAL ASPECTS OF GRANT FUNDS AWARDED TO ENTITIES INSIDE OF THE US. SPONSORED INSTITUTIONS ARE REQUIRED TO SUBMIT ANNUAL REPORTS OF EXPENDITURES AS WELL AS SCIENTIFIC PROGRESS REPORTS. SCIENTIFIC REPORTS ARE REVIEWED BY THE ORGANIZATION'S SCIENTIFIC STAFF TO ENSURE ACCEPTABLE PROGRESS HAS BEEN ATTAINED. THE FINAL GRANT PAYMENT IS CONTINGENT UPON RECEIPT AND APPROVAL OF THE REPORT OF EXPENDITURES. REPORTS OF EXPENDITURES ARE REVIEWED AND APPROVED BY STAFF TO ENSURE INCURRED COSTS ARE APPROPRIATE. THE CF FOUNDATION'S INTERNAL AUDITORS CONDUCT AUDITS ON SAMPLES OF GRANT EXPENDITURE REPORTS BY EXAMINING SUPPORTING RECORDS FROM THE SPONSORED INSTITUTIONS.Explanation

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeXCompensationCommittee
Independent ConsultantXIndependentConsultant
Form990 Of Other OrganizationsXForm990OfOtherOrganizations
Written Employment ContractXWrittenEmploymentContract
Compensation SurveyXCompensationSurvey
Board Or Committee ApprovalXBoardOrCommitteeApproval
Severance PaymentfalseSeverancePayment
Supplemental Nonqual Retire PlantrueSupplementalNonqualRetirePlan
Equity Based Comp ArrangementfalseEquityBasedCompArrangement
Comp Based On Revenue Of Filing OrgfalseCompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related OrgsfalseCompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing OrgfalseCompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate OrgsfalseCompBasedNetEarningsRelateOrgs
Any Non Fixed PaymentsfalseAnyNonFixedPayments
Initial Contract ExceptionfalseInitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (6 entries)

Base Compensation Filing OrgBaseCompensationFilingOrgComp Based On Related OrgsCompBasedOnRelatedOrgsBonus Filing OrgBonusFilingOrgBonus Related OrgsBonusRelatedOrgsOther Compensation Filing OrgOtherCompensationFilingOrgOther Compensation Related OrgsOtherCompensationRelatedOrgsDeferred Comp Filing OrgDeferredCompFilingOrgDeferred Comp Related OrgsDeferredCompRelatedOrgsNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgNontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgsTotal Compensation Filing OrgTotalCompensationFilingOrgTotal Compensation Related OrgsTotalCompensationRelatedOrgs
Robert J Beall PhD
16855633387357997117753793525439104851238007019314339339734386
Preston W Campbell MD
118606229481323096559654451570171573170443026877227933508098
C Richard Mattingly
035801809555302174902673450171140759779
Vera H Twigg
02442330629930180020936940262610445183
BRUCE MARSHALL MD
28827104886002322025128090103654820
MARTIN MENSE
142786018200028901635302746102050890

Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
SUPPLEMENTAL NONQUALIFIED RETIREMENT PLANPART I, LINE 4BPART I, LINE 4B: CERTAIN PERSONS LISTED IN FORM 990, PART VII, SECTION A PARTICIPATE IN A NONQUALIFIED DEFERRED COMPENSATION PLAN, UNDER WHICH INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO DESIGNATED VESTING DATE. FURTHER INFORMATION ABOUT THE NONQUALIFIED DEFERRED COMPENSATION PLAN IN WHICH THOSE PERSONS PARTICIPATE IS PROVIDED IN THE ADDITIONAL INFORMATION FOR SCHEDULE J, PART II, BELOW.
COMPENSATIONPART IICYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (A) NAME: R. BEALL, PH.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $161,296, 401(K) BONUS - $7,260; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $57,997; (B)(III) OTHER REPORTABLE COMPENSATION: HEALTH INSURANCE BENEFIT - $1,434, AUTOMOBILE ALLOWANCE - $2,376, OTHER BENEFITS INCLUDING GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $4,125; (C) DEFERRED COMPENSATION: LONG-TERM INCENTIVE PLAN BENEFIT (6) - $72,511, SERP (3) - $32,340; (D) NONTAXABLE BENEFITS: $0 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: R. BEALL, PH.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $319,133, 401(K) BONUS - $14,740; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $117,753; (B)(III) OTHER REPORTABLE COMPENSATION: HEALTH INSURANCE BENEFIT - $2,912, AUTOMOBILE ALLOWANCE - $4,824, OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $17,703; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $147,219, SERP (3) - $65,660; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $10,968, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $4,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,346 CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $118,606; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $32,309; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN (5) - $5,445; (C) DEFERRED COMPENSATION: LONG-TERM INCENTIVE PLAN BENEFIT (6) - $53,378, SERP (4) - $18,195; (D) NONTAXABLE BENEFITS: $0 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: P. CAMPBELL, M.D.; (B)(I) BASE COMPENSATION: BASE SALARY - $229,481; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $65,596; (B)(III) OTHER REPORTABLE COMPENSATION: OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $4,646, SECTION 457(B) PLAN (5) - $11,055; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $108,374, SERP (4) - $36,941; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $15,552, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $5,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $6,325 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. NAME: (A) R. MATTINGLY; (B)(I) BASE COMPENSATION: BASE SALARY - $358,018; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $95,553; (B)(III) OTHER REPORTABLE COMPENSATION: SECTION 457(B) PLAN (5) - $16,500; OTHER BENEFITS INCLUDING TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $5,249; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $163,713, SERP (4) - $78,504; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $10,968, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $1,800, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,346 CYSTIC FIBROSIS FOUNDATION - HEADQUARTERS. EIN 13-1930701. (A) NAME: V. TWIGG; (B)(I) BASE COMPENSATION: BASE SALARY - $244,233; (B)(II) BONUS & INCENTIVE COMPENSATION: ANNUAL INCENTIVE PLAN BENEFIT (1) - $62,993; (B)(III) OTHER REPORTABLE COMPENSATION: TAXABLE GENERAL ORGANIZATION GROUP TERM LIFE INSURANCE PREMIUM - $1,611, SECTION 457(B) PLAN (5) - $16,391; (C) DEFERRED COMPENSATION: RETIREMENT BENEFIT (2) - $25,128, LONG-TERM INCENTIVE PLAN BENEFIT (6) - $68,566; (D) NONTAXABLE BENEFITS: EMPLOYER CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $16,571, EMPLOYEE CONTRIBUTION TO FLEXIBLE SPENDING ACCOUNT BENEFIT - $5,000, EMPLOYEE CONTRIBUTION TO GENERAL ORGANIZATION HEALTH PLAN BENEFIT - $4,690 (1) THIS IS AN AWARD BASED ON ACHIEVEMENT OF ANNUAL PERFORMANCE STANDARDS ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE CFF BOARD. (2) THIS IS THE EMPLOYER CONTRIBUTION MADE UNDER THE CYSTIC FIBROSIS FOUNDATION 401(K) PLAN FOR THE 2011 PLAN YEAR. (3) THE SERP IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE SERP. A. THIS IS AN UNVESTED EMPLOYER CONTRIBUTION TO THE SERP. B. SERP INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO DECEMBER 31, 2012. C. SERP INTERESTS ARE HELD IN A TRUST SUBJECT TO THE CLAIMS OF CFF'S BANKRUPTCY CREDITORS. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS WOULD BECOME GENERAL UNSECURED CREDITORS OF CFF. D. THE SERP IS A NONQUALIFIED DEFERRED COMPENSATION PLAN. THIS MEANS THAT PARTICIPANTS DO NOT RECEIVE THE TAX BENEFITS AVAILABLE TO PARTICIPANTS IN TAX QUALIFIED RETIREMENT PLANS. FOR EXAMPLE, UNDER CURRENT LAW, INTERESTS UNDER SERPS ARE REPORTABLE AS TAXABLE COMPENSATION WHEN THEY BECOME VESTED, EVEN IF THOSE AMOUNTS ARE NOT YET PAYABLE TO THE PARTICIPANT (AND EVEN IF THOSE AMOUNTS ARE NEVER PAID TO THE PARTICIPANT). E. THE SERP'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. SERP CONTRIBUTION AMOUNTS WERE DETERMINED BY AN INDEPENDENT ACTUARY. F. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE SERP AT ANY TIME. (4) THE SERP IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE SERP. A. THIS IS AN UNVESTED EMPLOYER CONTRIBUTION TO THE SERP. B. SERP INTERESTS ARE FORFEITED BY THE PARTICIPANT IF THE PARTICIPANT VOLUNTARILY TERMINATES EMPLOYMENT PRIOR TO ATTAINING AGE 60. C. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS ARE GENERAL UNSECURED CREDITORS OF CFF. D. THE SERP IS A NONQUALIFIED DEFERRED COMPENSATION PLAN. THIS MEANS THAT PARTICIPANTS DO NOT RECEIVE THE TAX BENEFITS AVAILABLE TO PARTICIPANTS IN TAX QUALIFIED RETIREMENT PLANS. FOR EXAMPLE, UNDER CURRENT LAW, INTERESTS UNDER SERPS ARE REPORTABLE AS TAXABLE COMPENSATION WHEN THEY BECOME VESTED, EVEN IF THOSE AMOUNTS ARE NOT YET PAYABLE TO THE PARTICIPANT (AND EVEN IF THOSE AMOUNTS ARE NEVER PAID TO THE PARTICIPANT). E. THE SERP'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. AN INDEPENDENT ACTUARY DEVELOPED THE CONTRIBUTION FORMULA PURSUANT TO WHICH SERP CONTRIBUTION AMOUNTS ARE DETERMINED. F. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE SERP AT ANY TIME. (5) THE 457(B) PLAN IS SPONSORED BY CFF, A RELATED ORGANIZATION. THE EXECUTIVE PARTICIPATES BY VIRTUE OF BEING AN OFFICER OF CFF. CFFT MAKES CONTRIBUTIONS ON THE PARTICIPANT'S BEHALF TO THE PLAN. A. THIS IS A VESTED CONTRIBUTION TO THE 457(B) PLAN FOR THE REPORTING PERIOD. B. IN THE EVENT OF A CFF BANKRUPTCY, PARTICIPANTS ARE GENERAL UNSECURED CREDITORS OF CFF. C. DISTRIBUTIONS FROM THE 457(B) PLAN MAY NOT BE ROLLED-OVER TO AN IRA OR QUALIFIED PLAN (BUT MAY ONLY BE ROLLED-OVER TO ANOTHER 457(B) PLAN). D. THE 457(B) PLAN'S DESIGN WAS REVIEWED AND OPINED UPON AS REASONABLE BY AN INDEPENDENT COMPENSATION CONSULTANT. AN INDEPENDENT ACTUARY DEVELOPED THE CONTRIBUTION FORMULA PURSUANT TO WHICH 457(B) CONTRIBUTION AMOUNTS ARE DETERMINED. CONTRIBUTIONS TO THE 457(B) PLAN ARE SUBJECT TO ANNUAL IRS LIMITS (CURRENTLY $16,500). E. CFF RETAINS THE RIGHT TO AMEND OR TERMINATE THE 457(B) PLAN AT ANY TIME. (6) THIS PLAN PROVIDES FOR AWARDS THAT RELATE TO A THREE-YEAR PERFORMANCE PERIOD, BASED ON ACHIEVEMENT OF PERFORMANCE OBJECTIVES ESTABLISHED IN ADVANCE BY THE COMPENSATION COMMITTEE OF THE BOARD. EACH YEAR, A NEW THREE YEAR PERFORMANCE PERIOD BEGINS. AS REQUIRED BY THE FORM 990 INSTRUCTIONS, THE AMOUNTS REPORTED ON THIS FORM 990 REFLECT AN ESTIMATE OF THE PORTION OF EACH AWARD THAT THE EXECUTIVE ACCRUED UNDER THE PLAN FOR PERFORMANCE IN 2011 (I.E., WITH RESPECT TO THE 2010-2012 AND THE 2011-2013 PERFORMANCE PERIODS), BUT THE AMOUNTS REPORTED HAVE NOT BEEN EARNED, AWARDED OR PAID UNDER THE PLAN. THE INDIVIDUAL MUST BE EMPLOYED ON 12/31/12 AND 12/31/13 TO BE ELIGIBLE TO RECEIVE FULL PAYMENT OF THE AWARD FOR THE 2010-2012 AND THE 2011-2013 PERFORMANCE PERIODS, RESPECTIVELY.

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (10 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
GOVERNING BODY APPOINTMENTSPart VI, Section A, Line 7a (Page 6 Core Form)CERTAIN OF THE ORGANIZATION'S BOARD MEMBERS ARE DESIGNATED BY THE BOARD OF TRUSTEES OF THE CYSTIC FIBROSIS FOUNDATION.
REVIEW OF 990 BY GOVERNING BODYPart VI, Section B, Line 11b (Page 6 Core Form)THE ORGANIZATION'S BOARD OF DIRECTORS RECEIVES A DRAFT OF THE FORM 990 PRIOR TO ITS BEING FILED, WITH SUFFICIENT TIME FOR REVIEW AND COMMENT ALLOWED. THE ORGANIZATION'S ERISA ATTORNEYS REVIEW THE EXECUTIVE COMPENSATION SECTIONS OF THE FORM 990 TO ENSURE COMPLETENESS AND ACCURACY. THE AUDIT COMMITTEE ALSO REVIEWS THE FORM 990 AS PART OF ITS CHARTERED RESPONSIBILITIES.
CONFLICT OF INTEREST MONITORINGPart VI, Section B, Line 12c (Page 6 Core Form)A CONFLICT OF INTEREST DISCLOSURE STATEMENT IS COMPLETED ANNUALLY BY EACH BOARD MEMBER AND OFFICER. DISCLOSURES PROVIDED ARE REPORTED TO THE NOMINATING AND GOVERNANCE COMMITTEE, THE AUDIT COMMITTEE AND THE BOARD OF TRUSTEES. AS REQUIRED WITHIN THE BYLAWS, ANY POTENTIAL CONFLICTS OF INTEREST MUST BE REPORTED TO THE BOARD AS THEY ARISE. WHEN ANY MATTER IS DEEMED A POTENTIAL CONFLICT OF INTEREST AND REQUIRES ACTION BY THE BOARD OF TRUSTEES, THE INTERESTED TRUSTEE OR OFFICER IS REQUIRED TO RETIRE FROM THE ROOM IN WHICH THE BOARD OR ITS COMMITTEE IS MEETING, MAY NOT PARTICIPATE IN THE FINAL DELIBERATION OF THE MATTER, AND MAY NOT VOTE ON THE MATTER. THE ORGANIZATION ENFORCED THE POLICY DURING 2011 AND HAD NO CONFLICTS OF INTEREST AS DEFINED BY THE POLICY.
DETERMINING COMPENSATIONPart VI, Section B, Line 15a and 15b (Page 6 Core Form)THE TOTAL COMPENSATION OF EXECUTIVES AT THE CYSTIC FIBROSIS FOUNDATION IS SPECIFICALLY DESIGNED TO ATTRACT AND RETAIN THE HIGHEST QUALIFIED EXECUTIVE AND MEDICAL TALENT TO FULFILL THE CRITICALLY IMPORTANT MISSION OF ASSURING THE DEVELOPMENT OF THE MEANS TO CURE AND CONTROL CF AND IMPROVING THE QUALITY OF LIFE FOR THOSE WITH THE DISEASE. THE INDEPENDENT COMPENSATION COMMITTEE OF THE CF FOUNDATION'S BOARD OF TRUSTEES FOLLOWS THE PROCESS DESCRIBED IN THE IRS INTERMEDIATE SANCTIONS RULES WHEN DETERMINING COMPENSATION. SPECIFICALLY, THE COMMITTEE: 1. IS COMPOSED ENTIRELY OF NON-EMPLOYEE VOLUNTEER DIRECTORS WHO HAVE NO FAMILIAL, BUSINESS OR SIGNIFICANT PERSONAL RELATIONSHIPS WITH THE CF FOUNDATION OR ITS EXECUTIVES. 2. ASSESSES THE SHORT-TERM AND LONG-TERM CONTRIBUTION AND PERFORMANCE OF EACH EXECUTIVE IN MEETING VERY DEFINITIVE AND QUANTIFIABLE OBJECTIVES FOCUSED ON THE CF FOUNDATION'S MISSION SUCCESS. 3. ENGAGES AN INDEPENDENT COMPENSATION CONSULTING FIRM TO COMPILE APPROPRIATE COMPARABILITY DATA (INCLUDING COMPENSATION MARKET INFORMATION FOR PEERS WITH WHOM THE CF FOUNDATION COMPETES FOR EXECUTIVE TALENT) FOR COMMITTEE RELIANCE. THE COMMITTEE MEETS WITH REPRESENTATIVES OF THE CONSULTING FIRM TO REVIEW THIS DATA IN DETAIL. 4. REVIEWS ALL ELEMENTS OF EACH EXECUTIVE'S TOTAL COMPENSATION, INCLUDING BUT NOT LIMITED TO BASE SALARY, BONUSES, PERQUISITES, FRINGE BENEFITS, AND INCENTIVE AND DEFERRED COMPENSATION ARRANGEMENTS. UPON THE EXECUTIVE'S HIRE, AND AT EACH POINT IN TIME THEREAFTER AT WHICH A NEW OR REVISED COMPENSATION ARRANGEMENT IS UNDER CONSIDERATION WITH RESPECT TO THE EXECUTIVE, THE COMMITTEE MEETS WITH ITS INDEPENDENT COMPENSATION CONSULTING FIRM BEFORE THE ARRANGEMENT IS IMPLEMENTED TO EVALUATE THE REASONABLENESS OF THE ARRANGEMENT BY COMPARING BOTH THE ARRANGEMENT ITSELF AND THE EXECUTIVE'S ENTIRE COMPENSATION PACKAGES TO COMPENSATION PACKAGES PAID BY SIMILARLY SITUATED ORGANIZATIONS FOR FUNCTIONALLY COMPARABLE POSITIONS. 5. DOCUMENTS, CONCURRENTLY WITH ITS DETERMINATION, THE BASIS FOR ITS DETERMINATION IN THE MINUTES OF ITS MEETING. THESE MINUTES ARE REVIEWED, REVISED IF NECESSARY AND APPROVED AT THE FOLLOWING MEETING OF THE COMMITTEE. 6. OBTAINS A WRITTEN LEGAL OPINION CONCERNING THE COMMITTEE'S COMPLIANCE WITH THE IRS INTERMEDIATE SANCTIONS RULES. THE PROCESS DESCRIBED ABOVE WAS LAST USED IN 2009 TO ESTABLISH COMPENSATION FOR THE FOLLOWING OFFICERS OR POSITIONS: PRESIDENT & CEO EXECUTIVE VICE PRESIDENT & COO EXECUTIVE VICE PRESIDENT FOR MEDICAL AFFAIRS SENIOR VICE PRESIDENT & CFO IN ADDITION, IN DECEMBER 2010, THE COMPENSATION COMMITTEE REVIEWED THE EXECUTIVES' PERFORMANCE, RECENT INDEPENDENTLY PREPARED COMPENSATION DATA, AND OTHER CHANGES RELEVANT TO THE ENVIRONMENT OF THE CF FOUNDATION TO APPROVE INCREASES IN THE EXECUTIVES' SALARY FOR CALENDAR YEAR 2011. THE COMPENSATION COMMITTEE DOCUMENTED THE BASIS FOR ITS DETERMINATION IN THE MINUTES OF ITS MEETING. THESE MINUTES WERE REVIEWED AND APPROVED AT THE FOLLOWING MEETING OF THE COMPENSATION COMMITTEE.
PUBLIC INSPECTIONPart VI, Section C, Line 19 (Page 6 Core Form)THE FORM 1023 FOR THE ORGANIZATION WAS AVAILABLE ON ITS WEBSITE, CFF.ORG AND THE ORGANIZATION'S WEBSITE PROVIDES A LINK TO GUIDESTAR.ORG FOR ACCESS TO FORM 990. CFFT'S GOVERNING DOCUMENTS (BYLAWS AND ARTICLES OF INCORPORATION) ARE AVAILABLE UPON REQUEST BY CONTACTING THE NATIONAL OFFICE OF THE CYSTIC FIBROSIS FOUNDATION IN WRITING OR BY PHONE. INFORMATION ON HOW TO OBTAIN THE GOVERNING DOCUMENTS IS AVAILABLE ON THE WEBSITE, WWW.CFF.ORG/RESEARCH/CFFT. THE BOARD AND OFFICER CONFLICT OF INTEREST POLICY AND THE AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON THE WEBSITE, WWW.CFF.ORG/RESEARCH/CFFT.
COMPENSATION OF OFFICERS, DIRECTORS, TRUSTEES, ETCFORM 990, PART VII, SECTION ANAME AND TITLE THEODORE J. TORPHY,PH.D, CHAIRMAN AVG HRS WORKED 5 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE STEVEN SHAK, MD., DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE CATHERINE C. MCLOUD, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JONATHAN COHN, MD, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE JASON M. ARYEH, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE D. PAUL FLESSNER, DIRECTOR AVG HRS WORKED 3 HRS POSITION DIRECTOR REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG NONE NAME AND TITLE ROBERT J. BEALL, PH.D, PRES/CEO AVG HRS WORKED 18 HRS POSITION DIRECTOR & OFFICER REPORTABLE COMP FROM THE ORG 234,488 REPORTABLE COMP FROM RELATED ORG 477,065 EST. AMT OF OTHER COMP FROM THE ORG 362,172 NAME AND TITLE PRESTON W. CAMPBELL, M.D., EXEC VP OF MEDICAL AFFAIRS AVG HRS WORKED 18 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG 156,360 REPORTABLE COMP FROM RELATED ORG 310,778 EST. AMT OF OTHER COMP FROM THE ORG 268,893 NAME AND TITLE C. RICHARD MATTINGLY, EXEC VP/COO AVG HRS WORKED 5 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 475,320 EST. AMT OF OTHER COMP FROM THE ORG 284,459 NAME AND TITLE VERA H. TWIGG, SR VP & CFO AVG HRS WORKED 5 HRS POSITION OFFICER REPORTABLE COMP FROM THE ORG NONE REPORTABLE COMP FROM RELATED ORG 325,228 EST. AMT OF OTHER COMP FROM THE ORG 119,955 NAME AND TITLE BRUCE MARSHALL, MD, VP OF CLINICAL AFFAIRS AVG HRS WORKED 50 HRS POSITION KEY EMPLOYEE REPORTABLE COMP FROM THE ORG 339,453 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 26,029 NAME AND TITLE CYNTHIA GEORGE, MDS, FNP, BC DIRECTOR OF CLINICAL RESOURCES AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 111,524 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 15,333 NAME AND TITLE MARTIN MENSE, PH.D, PRINCIPAL SCIENTIST FOR DRUG DISCOVERY AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 161,275 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 43,814 NAME AND TITLE ELIZABETH JOSELOFF, PH.D. INTEGRATIVE BIOLOGY DIRECTOR AVG HRS WORKED 50 HRS POSITION HIGHEST COMPENSATED EMPLOYEE REPORTABLE COMP FROM THE ORG 103,125 REPORTABLE COMP FROM RELATED ORG NONE EST. AMT OF OTHER COMP FROM THE ORG 27,904 TOTAL REPORTABLE COMP FROM THE ORG 1,106,225 TOTAL REPORTABLE COMP FROM RELATED ORG 1,588,391 TOTAL EST. AMT OF OTHER COMP FROM THE ORG 1,148,559
HOURS DEVOTED FOR RELATED ORGANIZATIONFORM 990 PART VIINAME:Robert J. Beall, Ph.D. TITLE:President & CEO HOURS:39
HOURS DEVOTED FOR RELATED ORGANIZATIONFORM 990 PART VIINAME:Preston W. Campbell, MD TITLE:Exec VP of Medical Affairs HOURS:39
HOURS DEVOTED FOR RELATED ORGANIZATIONFORM 990 PART VIINAME:C. Richard Mattingly TITLE:Exec VP and COO HOURS:55
HOURS DEVOTED FOR RELATED ORGANIZATIONFORM 990 PART VIINAME:Vera H. Twigg TITLE:Sr. VP and CFO HOURS:55

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII (2 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEINEINPrimary ActivitiesPrimaryActivitiesLegal Domicile StateLegalDomicileStateExempt Code SectionExemptCodeSectionPublic Charity StatusPublicCharityStatusBusiness Name Line1DirectControllingEntityName/BusinessNameLine1Controlled OrgControlledOrg
CYSTIC FIBROSIS FOUNDATION-HEADQUARTERS
6931 ARLINGTON RDbethesdaMD20814131930701researchDE501(c)(3)7nafalse
CYSTIC FIBROSIS FOUNDATION - GROUP
6931 ARLINGTON RDBETHESDAMD20814136161105EDUCATIONDE501(c)(3)7CFF-HQfalse

Form990 Schedule R Part IV Form990ScheduleRPartIV

Name Of Related Org NameOfRelatedOrg

FieldValueIRS element (for citing)
Business Name Line1CYSTIC FIBROSIS SERVICES INCBusinessNameLine1

Address US AddressUS

FieldValueIRS element (for citing)
Address Line16931 ARLINGTON RDAddressLine1
CityBETHESDACity
StateMDState
ZIP Code20814ZIPCode
FieldValueIRS element (for citing)
EIN521850490EIN
Primary ActivitypharmacyPrimaryActivity
Legal Domicile StateMDLegalDomicileState

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1CFF PHARMACYBusinessNameLine1
FieldValueIRS element (for citing)
Type Of EntitycTypeOfEntity
FieldValueIRS element (for citing)
Receipt Of Int Ann Rents RoyaltiesfalseReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other OrgfalseGiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other OrgtrueGiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other OrgfalseLoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other OrgfalseLoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other OrgfalseSaleOfAssetsToOtherOrg
Purchase Of Assets From Other OrgfalsePurchaseOfAssetsFromOtherOrg
Exchange Of AssetsfalseExchangeOfAssets
Rental Of Facilities To Other OrgsfalseRentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other OrgsfalseRentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other OrgsfalsePerformOfServicesForOtherOrgs
Perform Of Services By Other OrgsfalsePerformOfServicesByOtherOrgs
Sharing Of FacilitiestrueSharingOfFacilities
Sharing Of Paid EmployeestrueSharingOfPaidEmployees
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrg
Reimbursement Paid By Other OrgfalseReimbursementPaidByOtherOrg
Other Transfer To Other OrgfalseOtherTransferToOtherOrg
Other Transfer From Other OrgfalseOtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable (3 entries)

Transaction TypeTransactionTypeAmount InvolvedAmountInvolvedMethod Of Amt DeterminationMethodOfAmtDetermination
Cystic fibrosis foundation - headquarters
1c49932523FMV
Cystic fibrosis foundation - headquarters
1M255145FMV
Cystic fibrosis foundation - headquarters
1N1640186FMV